Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. As existing methods for the development and characterization of IgG-ADCs are not compatible with IgM-ADC, we describe a platform methodology suitable for site specific IgM-ADC using a chemoenzymatic method targeting the glycans on the IgM. Azide functionalized sialic acids were incorporated onto IgM glycans using sialyltransferase for biocompatible conjugation using "click" chemistry. The number of azide groups incorporated onto the IgM glycans were characterized by mass spectrometry of the enzymatically released glycans and glycopeptides. Quantitation of the azide incorporation showed an azide antibody ratio of 8 (glycan data) and 6–10 (glycopeptide data) which translates to a high drug antibody ratio based on IgG-ADC standards. This platform methodology can be readily adapted for any human IgM produced in a mammalian cell expression system.

LanguageEnglish
Article number113385
Number of pages7
JournalAnalytical Biochemistry
Volume584
DOIs
Publication statusPublished - 1 Nov 2019

Fingerprint

Labeling
Polysaccharides
Immunoglobulin M
Azides
Antibodies
Pharmaceutical Preparations
Glycopeptides
Immunoglobulin G
Click Chemistry
Sialyltransferases
Sialic Acids
Glycosylation
Complement Activation
Debris
Quality Control
Quality control
Mass spectrometry
Mass Spectrometry
Molecular Weight
Chemical activation

Keywords

  • IgM
  • Antibody-drug conjugate
  • Click chemistry
  • Drug-antibody ratio
  • Glycans
  • Glycopeptides

Cite this

@article{da51667f74574c95a99251c6dc7ecd32,
title = "Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates",
abstract = "Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. As existing methods for the development and characterization of IgG-ADCs are not compatible with IgM-ADC, we describe a platform methodology suitable for site specific IgM-ADC using a chemoenzymatic method targeting the glycans on the IgM. Azide functionalized sialic acids were incorporated onto IgM glycans using sialyltransferase for biocompatible conjugation using {"}click{"} chemistry. The number of azide groups incorporated onto the IgM glycans were characterized by mass spectrometry of the enzymatically released glycans and glycopeptides. Quantitation of the azide incorporation showed an azide antibody ratio of 8 (glycan data) and 6–10 (glycopeptide data) which translates to a high drug antibody ratio based on IgG-ADC standards. This platform methodology can be readily adapted for any human IgM produced in a mammalian cell expression system.",
keywords = "IgM, Antibody-drug conjugate, Click chemistry, Drug-antibody ratio, Glycans, Glycopeptides",
author = "Moh, {Edward S. X.} and Nima Sayyadi and Packer, {Nicolle H.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.ab.2019.113385",
language = "English",
volume = "584",
journal = "Analytical Biochemistry",
issn = "0003-2697",
publisher = "Academic Press",

}

Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates. / Moh, Edward S. X.; Sayyadi, Nima; Packer, Nicolle H.

In: Analytical Biochemistry, Vol. 584, 113385, 01.11.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates

AU - Moh,Edward S. X.

AU - Sayyadi,Nima

AU - Packer,Nicolle H.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. As existing methods for the development and characterization of IgG-ADCs are not compatible with IgM-ADC, we describe a platform methodology suitable for site specific IgM-ADC using a chemoenzymatic method targeting the glycans on the IgM. Azide functionalized sialic acids were incorporated onto IgM glycans using sialyltransferase for biocompatible conjugation using "click" chemistry. The number of azide groups incorporated onto the IgM glycans were characterized by mass spectrometry of the enzymatically released glycans and glycopeptides. Quantitation of the azide incorporation showed an azide antibody ratio of 8 (glycan data) and 6–10 (glycopeptide data) which translates to a high drug antibody ratio based on IgG-ADC standards. This platform methodology can be readily adapted for any human IgM produced in a mammalian cell expression system.

AB - Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. As existing methods for the development and characterization of IgG-ADCs are not compatible with IgM-ADC, we describe a platform methodology suitable for site specific IgM-ADC using a chemoenzymatic method targeting the glycans on the IgM. Azide functionalized sialic acids were incorporated onto IgM glycans using sialyltransferase for biocompatible conjugation using "click" chemistry. The number of azide groups incorporated onto the IgM glycans were characterized by mass spectrometry of the enzymatically released glycans and glycopeptides. Quantitation of the azide incorporation showed an azide antibody ratio of 8 (glycan data) and 6–10 (glycopeptide data) which translates to a high drug antibody ratio based on IgG-ADC standards. This platform methodology can be readily adapted for any human IgM produced in a mammalian cell expression system.

KW - IgM

KW - Antibody-drug conjugate

KW - Click chemistry

KW - Drug-antibody ratio

KW - Glycans

KW - Glycopeptides

UR - http://www.scopus.com/inward/record.url?scp=85070107281&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/arc/CE140100003

U2 - 10.1016/j.ab.2019.113385

DO - 10.1016/j.ab.2019.113385

M3 - Article

VL - 584

JO - Analytical Biochemistry

T2 - Analytical Biochemistry

JF - Analytical Biochemistry

SN - 0003-2697

M1 - 113385

ER -